Abstract     Description     Claims     Drawing  

JP2016214785A   [0013] 
JP2017151547A   [0013] 

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer   [0003] 
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients with Platinum-Resistant Ovarian Cancer   [0003] 
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma   [0003] 
Immunity   [0085] 
Science   [0085] 
Nat. Med.   [0085] 
Microbiota: a key orchestrator of cancer therapy   [0112] 
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-Ll efficacy   [0112] 
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota   [0112] 
Gut Microbes May Up PD-1 Inhibitor Response   [0112] 
Differences in gut microbial metabolism are responsible for reduced hippurate synthesis in Crohn's disease   [0112] 
Symbiotic gut microbes modulate human metabolic phenotypes   [0112] 
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer   [0112]